Stockwinners Market Radar for January 07, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Celgene (CELG) and Impact Biomedicines announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1B upfront and up to $1.25B in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible. 2. Pfizer (PFE) will stop trying to discover new drugs for Alzheimer's disease and Parkinson's disease, according to The Wall Street Journal. The move will result in layoffs of 300 employees over several months, the report added. 3. U.S. postal rates look likely to rise, pinching Amazon (AMZN) and benefiting FedEx (FDX) and UPS (UPS), Jack Hough wrote in this week's edition of Barron's. While for now UPS enjoys higher profit margins, investors should favor FedEx as years-long investment in automating and expanding its hubs has given the company a speed and efficiency advantage over the former, he added. Earnings per share growth for FedEx should more than triple next year as tax cuts kick in, the report noted. 4. Sony's (SNE) "Jumanji: Welcome to the Jungle" has topped the charts after three weekends in theaters, earning $36M from 3,801 theaters and bringing its total to $244.4M. The Dwayne Johnson and Kevin Hart-led remake has received an A- CinemaScore and got a 77% from Rotten Tomatoes. 5. Kohl's (KSS), Charles Schwab (SCHW), Home Depot (HD), Valero Energy (VLO), NextEra Energy (NEE), Allstate (ALL), Cisco Systems (CSCO), Las Vegas Sands (LVS), Wynn Resorts (WYNN), and Melco Resorts & Entertainment (MLCO), saw positive mentions in Barron's, while Caterpillar (CAT) was mentioned cautiously.

19:03 EDT Zymeworks announces 2018 priorities - Building on its 2017 accomplishments, over the next 12 months, Zymeworks expects to complete enrollment and report additional data from its adaptive Phase 1 clinical study of ZW25, refine the regulatory strategy and accelerate the development of ZW25, file an Investigational New Drug Application for one of its wholly-owned product candidates, present preclinical data showcasing its maturing candidate pipeline and evolving therapeutic platforms, and establish new strategic drug development partnerships. Additionally, Zymeworks expects its partners' Azymetric programs to begin entering the clinic in 2018.

18:03 EDT Celgene to acquire Impact Biomedicines, adds Fedratinib to pipeline - Celgene and Impact Biomedicines announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1B upfront and up to $1.25B in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible. Fedratinib, a highly selective JAK2 kinase inhibitor, was evaluated in 877 patients across 18 clinical trials. In a randomized, placebo-controlled, phase III pivotal trial for patients with treatment-naive myelofibrosis, fedratinib demonstrated statistically significant improvements in the primary and secondary endpoints of splenic response and total symptom score, respectively. In an exploratory subgroup analysis, these improvements were observed regardless of a patient's baseline platelet count. A multi-center, single-arm phase II trial evaluated fedratinib in myelofibrosis patients who were found to be resistant or intolerant to ruxolitinib, a JAK1/JAK2 inhibitor. In this second-line setting, fedratinib demonstrated clinically meaningful improvements in splenic response and total symptom score. JAKARTA-2 was stopped prematurely due to a clinical hold placed on the fedratinib program by the U.S. Food and Drug Administration after potential cases of Wernicke's encephalopathy were reported in eight out of 877 patients receiving one or more doses. The FDA removed the clinical hold in August 2017. Based on the reported benefit risk profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018.

17:10 EDT Alnylam expects Patisiran to be first commercially available RNAi in mid-2018 - Alnylam (ALNY) announced 2018 corporate goals, namely that it expects Patisiran to be first commercially available RNAi therapeutic in mid-2018, restructured Sanofi (SNY) Alliance to provide Alnylam with global commercial footprint for ATTR Amyloidosis, Givosiran Interim Phase 3 data in mid-2018 and U.S. New Drug Application filing in late 2018. The company also plans to advance three additional Phase 3 programs: Fitusiran, Inclisiran, and ALN-TTRsc02.

15:59 EDT MiMedx provides update to share repurchase program - MiMedx provided an update to its share repurchase program that was initiated in May 2014. The company reported that since inception, its Board of Directors has authorized $130M in share repurchases. To date, the number of shares purchased through the share repurchase program is $124.2M, and these repurchased shares represent in excess of 10% of the company's total diluted shares outstanding.

15:35 EDT Ultragenyx announces positive interim results from DTX301 study - Ultragenyx Pharmaceutical announced positive interim safety and efficacy data from the first dose cohort of the Phase 1/2 study of DTX301, an adeno-associated virus gene therapy for the treatment of ornithine transcarbamylase deficiency. "We are encouraged by these initial data showing activity with our AAV8 vector in patients in the first, lowest-dose cohort. Patient 1 showed a normalization of ureagenesis that was maintained through 12 weeks, and we view this initial efficacy data as clinically meaningful and a promising indication of the potential of DTX301," said Emil Kakkis, CEO and President of Ultragenyx. "Based on the data to date, we expect to be able to move to the higher-dose second cohort pending the data monitoring committee's review of the 12-week safety data for all three patients in this cohort, and data from this second cohort should be available in the second half of 2018."